US · CON · MEDICAL - CARE FACILITIES
Concentra Group Holdings Parent, Inc. (CON) intrinsic value and stock valuation
$41.84as of 2026-11-21 · Mkt cap 3.94B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Concentra Group Holdings Parent, Inc. DCF and intrinsic value
InvestorsCraft values CON with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from CON’s statements →
Concentra Group Holdings Parent, Inc. Graham Number
Graham Number: $10.10d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2021–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Integer Holdings Corporation (ITGR) $126.97
- Haemonetics Corporation (HAE) $120.16
- Beam Therapeutics Inc. (BEAM) $20.90
- DENTSPLY SIRONA Inc. (XRAY) $8.29
- Prestige Consumer Healthcare Inc. (PBH) $49.63
- Bausch Health Companies Inc. (BHC) $8.22
- Addus HomeCare Corporation (ADUS) $122.50
- HUTCHMED (China) Limited (HCM) $13.22
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.16B | $1.9B | $1.84B | $1.72B | $1.73B |
| Operating income | $2.09B | $304.8M | $287.6M | $258.2M | $270.3M |
| Net income | $172.8M | $166.5M | $180M | $166.7M | $208.9M |
| EPSd | $1.35M | $1.3M | $1.42M | $1.32M | $1.65M |
| Operating cash flow | $279.4M | $274.7M | $234.3M | $274.3M | $290.6M |
| Capital expenditure | -$-82.33M | -$-64.33M | -$-69.34M | -$-45.98M | -$-46.79M |
| Free cash flow | $197.1M | $210.4M | $165M | $228.4M | $243.9M |
| Total assets | $3.04B | $2.52B | $2.49B | $2.3B | — |
| Total debt | $2.1B | $1.95B | $905M | $1.04B | — |
| Net debt | $2.02B | $1.77B | $873.6M | $1B | — |
| Total equity | $420.4M | $298.7M | $1.18B | $996.1M | — |
| Cash and short-term investments | $79.9M | $183.3M | $31.4M | $37.7M | — |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.16B | $1.9B | $1.84B | $1.72B | $1.73B |
| Cost of revenue | $1.55B | $1.37B | $1.33B | $1.32B | $1.3B |
| Gross profit | $613.1M | $528M | $512.4M | $408.2M | $428M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $203.3M | $156.3M | $152M | $150M | $157.7M |
| Other expenses | -$-1.68B | $66.9M | $72.8M | $0.00 | $0.00 |
| Operating expenses | -$-1.47B | $223.2M | $224.8M | $150M | $157.7M |
| Cost and expenses | $75.8M | $1.6B | $1.55B | $1.47B | $1.46B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $109.3M | $69.7M | $114M | $31.6M | $31.9M |
| Depreciation and amortization | $75.8M | $67.2M | $73.1M | $73.7M | $82.2M |
| Ebitda | $408.9M | $368.3M | $360.2M | $330.2M | $389.6M |
| Operating income | $2.09B | $304.8M | $287.6M | $258.2M | $270.3M |
| Total other income/expenses, net | -$-1.86B | -$-73.37M | -$-45M | -$-33.32M | $5.3M |
| Income before tax | $223.8M | $231.4M | $242.6M | $224.9M | $275.6M |
| Income tax expense | $51M | $59.5M | $57.9M | $52.7M | $59.5M |
| Net income | $172.8M | $166.5M | $180M | $166.7M | $208.9M |
| Weighted average shares outstanding | $126.7M | $128.1M | $126.6M | $126.6M | $126.6M |
| Weighted average diluted shares outstanding | $128.2M | $128.1M | $126.6M | $126.6M | $126.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash and short-term investments | $79.9M | $183.3M | $31.4M | $37.7M |
| Net receivables | $257.9M | $217.7M | $216.2M | $206.3M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $383.1M | $437.2M | $294.4M | $284.6M |
| Property, plant and equipment, net | $709M | $633.5M | $576.2M | $533.9M |
| Goodwill and intangible assets | $1.72B | $1.44B | $1.45B | $1.47B |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $2.66B | $2.08B | $2.19B | $2.01B |
| Total assets | $3.04B | $2.52B | $2.49B | $2.3B |
| Accounts payable | $21M | $19.8M | $20.4M | $27.7M |
| Short-term debt | $95.3M | $85.5M | $74.4M | $73M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $50K |
| Total current liabilities | $337.3M | $307.2M | $274.6M | $279.6M |
| Long-term debt | $2.01B | $1.87B | $830.6M | $966.7M |
| Deferred revenue, non-current | $0.00 | $2.97M | $0.00 | $0.00 |
| Total non-current liabilities | $2.28B | $1.92B | $1.04B | $1.02B |
| Capital lease obligations | $445.3M | $475.3M | $357.3M | $404.1M |
| Total liabilities | $2.62B | $2.22B | $1.31B | $1.3B |
| Common stock | $1.29M | $1.28M | $470.3M | $464.7M |
| Retained earnings | $146.5M | $13.6M | $685.3M | $508.6M |
| Accumulated other comprehensive income (loss) | -$-3.35M | $0.00 | $0.00 | $0.00 |
| Total equity | $420.4M | $298.7M | $1.18B | $996.1M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $2.1B | $1.95B | $905M | $1.04B |
| Net debt | $2.02B | $1.77B | $873.6M | $1B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $172.8M | $171.9M | $184.7M | $172.2M | $216M |
| Depreciation and amortization | $0.00 | $67.2M | $73.1M | $73.7M | $82.2M |
| Stock-based compensation | $0.00 | $2.33M | $650K | $2.14M | $2.14M |
| Change in working capital | $7.96M | $30.2M | -$-18.7M | $33.9M | -$-7.28M |
| Accounts receivable | -$-11.14M | -$-1.6M | -$-10.26M | -$-5.93M | $12.5M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $18M | $24.6M | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $279.4M | $274.7M | $234.3M | $274.3M | $290.6M |
| Investments in property, plant and equipment | $0.00 | -$-64.33M | -$-69.34M | -$-45.98M | -$-46.79M |
| Acquisitions, net | $0.00 | -$-6.96M | -$-6M | -$-11.8M | -$-20.1M |
| Net cash used for investing activities | -$-414.86M | -$-71.27M | -$-75.31M | -$-57.75M | -$-61.8M |
| Common stock issued | $0.00 | $511.2M | $3.34M | $3.34M | $10.1M |
| Common stock repurchased | -$-22.42M | -$-15.4M | -$-5.32M | -$-29.05M | $0.00 |
| Dividends paid | -$-32.08M | -$-1.54B | -$-6.13M | $0.00 | $0.00 |
| Net cash used for financing activities | $32.1M | -$-51.53M | -$-165.29M | -$-209.86M | -$-342.59M |
| Net change in cash | -$-103.36M | $151.9M | -$-6.28M | $6.73M | -$-113.75M |
| Cash at end of period | $79.9M | $183.3M | $31.4M | $37.7M | $30.9M |
| Operating cash flow | $279.4M | $274.7M | $234.3M | $274.3M | $290.6M |
| Capital expenditure | -$-82.33M | -$-64.33M | -$-69.34M | -$-45.98M | -$-46.79M |
| Free cash flow | $197.1M | $210.4M | $165M | $228.4M | $243.9M |
Line items
Line items
Line items
About Concentra Group Holdings Parent, Inc.
Concentra Group Holdings Parent, Inc. is a U.S.-based provider of occupational health solutions. The company delivers a comprehensive suite of occupational and consumer health services, encompassing treatment for workers' compensation injuries, urgent care, diagnostic clinical testing, preventative health measures, and employer-specific programs, along with wellness initiatives. These services are accessible through their network of occupational health centers and onsite clinics. Furthermore, Concentra offers specialized solutions like Concentra Telemed, a telemedicine platform for addressing work-related injuries and illnesses and supporting employer services; Concentra Pharmacy, providing pharmaceutical solutions; and Concentra Medical Compliance Administration, a third-party administrative service that assists employers in managing drug abuse testing programs for both regulated and non-regulated workforces. Established in 1979 and headquartered in Mechanicsburg, Pennsylvania, the company functions as a subsidiary of Select Medical Corporation.
- CEO
- William Keith Newton
- Employees
- 13.13K
- Beta
- 0.69
Explore
Frequently asked questions
What is the intrinsic value of Concentra Group Holdings Parent, Inc. (CON)?
Concentra Group Holdings Parent, Inc. (CON) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CON undervalued?
CON trades at a price of $41.84 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.